Biotech News

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Talphera Inc (TLPH)Talphera2026-08-12 20:05 ESTEarnings

NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines Updated market research indicates an estimated 200,000 annual U.S.

Talphera Inc

Talphera is a specialty pharmaceutical company focused on acute-care and pain management products. Its story is centered on hospital-oriented therapies and the challenge of commercial execution in acute care.

Recent company news

TLPHTalphera2026-09-03 12:30 EST

Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

TLPHTalphera2026-08-12 20:05 EST